Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FZH82
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,095
Award facts
- Contract value 100% obligated
- $3,094.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $3,094.80 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/mL syringes, awarded on November 7, 2025, with an ultimate completion date of December 2, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order will be performed at the vendor's Park Ridge facility and represents a firm fixed-price purchase of this specialized immunosuppressant biologic product for Department of Defense medical supply needs.
This delivery order was issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to support recurring pharmaceutical and medical supply requirements for military healthcare facilities worldwide. The underlying IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for a comprehensive range of branded and generic pharmaceuticals, biologics, vaccines, and medical consumables. This delivery order exemplifies the contractor's role as a critical pharmaceutical supplier within the federal military medical supply chain, leveraging its established performance across diverse therapeutic categories to support DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FZH82?
SPE2DB26FZH82 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DB26FZH82 worth?
The government has obligated $3,095 on SPE2DB26FZH82.
Is contract SPE2DB26FZH82 an order under another contract?
Yes. SPE2DB26FZH82 is a delivery order under SPE2DB20D9329, an indefinite delivery contract.
Was contract SPE2DB26FZH82 competed?
The extent of competition for SPE2DB26FZH82 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award